In this third live discussion round, experts from Switzerland and Germany discuss practice-changing studies in the fields of GU, Immunoncology and Hematology with the ASCO2020 original authors.
The following authors are presenting their studies:
Dr. Thierry André
Sorbonne University and Saint-Antoine Hospital, Paris, France
Pembrolizumab Versus Chemotherapy for Microsatellite Instability-High/Mismatch Repair Deficient Metastatic Colorectal Cancer: The Phase 3 KEYNOTE-177 Study
Prof. Dr. Shaji Kumar
Mayo Clinic, Rochester, MN, USA
Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial.
Dr. Landon Carter Brown
Duke Cancer Institute, Durham, North Carolina, USA
Association of LRP1B pathogenic genomic alterations with favorable outcomes with immune checkpoint inhibitors across multiple tumor types.
Dr. Jesus G. Berdeja
Sarah Cannon Research Institute, Nashville, TN, USA
Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma.
Prof. Dr. Thomas Powles
Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, London, UK
Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis.
ASCO DirectTM is a multi-sponsoring project and one of the American Society of Clinical Oncology® (ASCO®) licensed services.